BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2017

View Archived Issues

Metacrine tests new farnesoid X-activated receptor agonist in NASH model

Read More

Armanezumab clears pathological Tau protein in mouse brains

Read More

Procathepsin D found as a diagnostic marker of malignant pleural effusion in lung cancer

Read More

Hepcidin knockout rats display iron overload

Read More

European Commission approves dinutuximab beta for the treatment of high-risk neuroblastoma

Read More

Adaptimmune Therapeutics begins AFP SPEAR T-cell study in HCC

Read More

FDA grants breakthrough therapy designation to vonapanitase from Proteon Therapeutics

Read More

First patient enrolled in phase I trial of Loxo Oncology's LOXO-292

Read More

Takeda and GammaDelta Therapeutics announce strategic collaboration

Read More

Leucyl-tRNA synthetase inhibitor from Dong-A ST potently inhibits Gram-negative bacteria

Read More

Polymorphism in ADRB1 impacts outcome in Marfan syndrome patients on atenolol

Read More

FDA grants fast track designation to Celyad's C-Cure

Read More

Astellas discontinues ASP-8273 treatment in SOLAR NSCLC trial

Read More

Vericel's ixmyelocel-T wins FDA regenerative medicine advanced therapy designation

Read More

Companies partner on E.U. managed access programs for niraparib and belinostat

Read More

A new rabbit model of respiratory distress syndrome managed on nCPAP

Read More

Savara receives FDA guidance on clinical requirements for Molgradex NDA

Read More

Longeveron cleared to continue phase I trial of LMSCs in Alzheimer's disease

Read More

Topline data reported from pivotal studies of mepolizumab for severe COPD

Read More

Shionogi reflects on accomplishments of fourth quarter of fiscal 2016

Read More

Jortan Pharmaceuticals discovers beta-secretase 2 inhibitors

Read More

NSAID derivatives patented by ratiopharm

Read More

AbGenomics initiates phase I study of ADC AbGn-107 in gastric, colorectal and pancreatic cancer

Read More

Sangamo and Pfizer collaborate on gene therapy programs for hemophilia A

Read More

FDA approves Keytruda in first-line combination therapy for metastatic nonsquamous NSCLC

Read More

Servier initiates phase I study of S-64315 in AML and MDS

Read More

Polymorphisms of the Wnt pathway associated with bronchopulmonary dysplasia in ELBW infants

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing